GSK3395879, with the CAS number 2215852-91-6, is a chemical compound that has been investigated primarily for its potential therapeutic applications. It belongs to a class of compounds known as small molecules, which are often designed to interact with specific biological targets, such as proteins or enzymes, to modulate their activity. The compound has been studied for its role in treating various conditions, particularly in the context of immunology and oncology. Its mechanism of action typically involves the inhibition of certain pathways that contribute to disease progression. In terms of physical properties, like many small molecules, GSK3395879 may exhibit characteristics such as solubility in organic solvents, stability under specific conditions, and a defined melting point, although these specific values are not universally available. As with any investigational drug, its safety, efficacy, and pharmacokinetic properties are evaluated through clinical trials before it can be considered for therapeutic use.

GSK3395879 is a potent, selective and orally active TRPV4 inhibitor (IC50 = 1 nM), GSK3395879 demonstrated the ability to inhibit TRPV4-mediated pulmonary edema in an in vivo rat model. GSK3395879 is a tool for studying the biology of TRPV4 and an advanced lead for identifying new heart failure medicines.

GSK3395879

2215852-91-6: GSK3395879, with the CAS number 2215852-91-6, is a chemical compound that has been investigated primarily for its potential therapeutic applications. It belongs to a class of compounds known as small molecules, which are often designed to interact with specific biological targets, such as proteins or enzymes, to modulate their activity. The compound has been studied for its role in treating various conditions, particularly in the context of immunology and oncology. Its mechanism of action typically involves the inhibition of certain pathways that contribute to disease progression. In terms of physical properties, like many small molecules, GSK3395879 may exhibit characteristics such as solubility in organic solvents, stability under specific conditions, and a defined melting point, although these specific values are not universally available. As with any investigational drug, its safety, efficacy, and pharmacokinetic properties are evaluated through clinical trials before it can be considered for therapeutic use.

<p>GSK 3395879 is a peptide that inhibits protein interactions. It can be used as a research tool to study various protein interactions, and also as an inhibitor or activator of receptor-ligand interactions. GSK 3395879 has been shown to inhibit the activity of ion channels, such as sodium channels, in neuronal cells. The peptide is a potent inhibitor of the human angiotensin II type 1 receptor with IC50 value of 0.4 nM, and it also binds to the angiotensin II type 2 receptor with IC50 value of 0.6 nM. GSK3395879 also inhibits high-affinity binding to the beta1-adrenergic receptor (IC50 = 3 nM) and alpha2C-adrenergic receptors (IC50=0.7 nM).</p>

GSK 3395879

<p>GSK3395879 is a selective and orally bioavailable antagonist of transient receptor potential vanilloid-4 (TRPV4)  (IC50: 1 nM for hTRPV4).</p>

CAS 2215852-91-6

GSK3395879

GSK 3395879

Ref: 3D-QND85291

GSK3395879

Ref: TM-T15439